Skip to main content
. Author manuscript; available in PMC: 2023 Jul 1.
Published in final edited form as: Curr Eye Res. 2022 Mar 28;47(7):1034–1042. doi: 10.1080/02713683.2022.2053166

Figure 4.

Figure 4.

Swelling ratios (a) and equilibrium water content (b) for dexamethasone, aflibercept and combination DDSs at varying temperatures. “DEX-DDS” had 20 mg/ml of dexamethasone nanoparticles, “AFL-DDS” had 20 mg/ml of aflibercept microparticles, and “Combo-DDS” had 20 mg/ml of dexamethasone nanoparticles and 20 mg/ml of aflibercept microparticles. Error bars represent standard error (n=3). Statistically significant difference (p < 0.05) between DEX-DDS and Combo-DDS is indicated by * and between AFL-DDS and Combo-DDS is indicated by #.